Prevention of Lyme disease: Promising research or sisyphean task?

Archivum Immunologiae et Therapiae Experimentalis

Volumn 59, Issue 4, 2011, Pages 261-275

  Krupka, Michal ^a   Zachova, Katerina ^a   Weigl, Evzen ^a   Raska, Milan ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Borrelia burgdorferi; Lyme disease; Osp; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BIOCAN B; GALAXY LYME; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 12; LYME DISEASE VACCINE; LYMEVAX; MERILYM; OUTER SURFACE PROTEIN A; OUTER SURFACE PROTEIN B; OUTER SURFACE PROTEIN C; PROLYME; RECOMBITEK LYME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; BACTERIAL STRAIN; BORRELIA BURGDORFERI; CYTOKINE PRODUCTION; DISEASE CARRIER; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION PREVENTION; IXODES; LYME DISEASE; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; REVIEW; TH1 CELL; TH2 CELL; UNITED STATES; ZOONOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENIC VARIATION; ANTIGENS, BACTERIAL; ANTIGENS, SURFACE; AUTOIMMUNE DISEASES; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; HUMANS; IXODES; LIPOPROTEINS; LYME DISEASE; MICE; MOLECULAR SEQUENCE DATA; UNITED STATES; VACCINATION;

EID: 79959581513     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-011-0128-z     Document Type: Review

References (189)

1. Alban PS, Johnson PW, Nelson DR (2000) Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology 146(Pt 1):119-127 (Pubitemid 30066313)
2. Alitalo A, Meri T, Ramo L et al (2001) Complement evasion by Borrelia burgdorferi: serum-resistant strains promote C3b inactivation. Infect Immun 69:3685-3691 (Pubitemid 32493285)
3. Anguita J, Ramamoorthi N, Hovius JW et al (2002) Salp15, an Ixodes scapularis salivary protein, inhibits CD4(+) T cell activation. Immunity 16:849-859 (Pubitemid 34786483)
4. Batsford S, Dunn J, Mihatsch M (2004) Outer surface lipoproteins of Borrelia burgdorferi vary in their ability to induce experimental joint injury. Arthritis Rheum 50:2360-2369
5. Beaufays J, Adam B, Decrem Y et al (2008) Ixodes ricinus tick lipocalins: identification, cloning, phylogenetic analysis and biochemical characterization. PLoS ONE 3:e3941
6. Belakova J, Krupka M, Sebestova M et al (2005) Preparation and purification of recombinant outer surface protein A (rOspA) of Borrelia burgdorferi sensu stricto and Borrelia afzelii. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:257-259
7. Belakova J, Horynova M, Krupka M et al (2007) DNA vaccines: are they still just a powerful tool for the future? Arch Immunol Ther Exp 55:387-398
8. Bernardino AL, Myers TA, Alvarez X et al (2008) Toll-like receptors: insights into their possible role in the pathogenesis of lyme neuroborreliosis. Infect Immun 76:4385-4395
9. Boardman BK, He M, Ouyang Z et al (2008) Essential role of the response regulator Rrp2 in the infectious cycle of Borrelia burgdorferi. Infect Immun 76:3844-3853
10. Bockenstedt LK, Fikrig E, Barthold SW et al (1993) Inability of truncated recombinant OspAproteins to elicit protective immunity to Borrelia burgdorferi in mice. J Immunol 151:900-906 (Pubitemid 23215755)
11. Bockenstedt LK, Fikrig E, Barthold SW et al (1996) Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice. J Immunol 157:5496-5502 (Pubitemid 126448970)
12. Brandt ME, Riley BS, Radolf JD et al (1990) Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins. Infect Immun 58:983-991
13. Brorson O, Brorson SH (1997) Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes. Infection 25:240-246 (Pubitemid 27348159)
14. Brorson O, Brorson SH (1998a) In vitro conversion of Borrelia burgdorferi to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium. Infection 26:144-150
15. Brorson O, Brorson SH (1998b) A rapid method for generating cystic forms of Borrelia burgdorferi, and their reversal to mobile spirochetes. APMIS 106:1131-1141 (Pubitemid 29075897)
16. Brown EL, Kim JH, Reisenbichler ES et al (2005) Multicomponent Lyme vaccine: three is not a crowd. Vaccine 23:3687-3696 (Pubitemid 40692414)
17. Buckles EL, Earnhart CG, Marconi RT (2006) Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine development. Clin Vaccine Immunol 13:1162-1165 (Pubitemid 44622545)
18. Burgdorfer W, Barbour AG, Hayes SF et al (1982) Lyme disease - a tick-borne spirochetosis? Science 216:1317-1319
19. Bykowski T, Woodman ME, Cooley AE et al (2008) Borrelia burgdorferi complement regulator-acquiring surface proteins (BbCRASPs): expression patterns during the mammal-tick infection cycle. Int J Med Microbiol 298(suppl 1):249-256
20. Cabello FC, Godfrey HP, Newman SA (2007) Hidden in plain sight: Borrelia burgdorferi and the extracellular matrix. Trends Microbiol 15:350-354 (Pubitemid 47126852)
21. Caimano MJ, Eggers CH, Gonzalez CA et al (2005) Alternate sigma factor RpoS is required for the in vivo-specific repression of Borrelia burgdorferi plasmid lp54-borne ospA and lp6.6 genes. J Bacteriol 187:7845-7852 (Pubitemid 41587721)
22. Caimano MJ, Iyer R, Eggers CH et al (2007) Analysis of the RpoS regulon in Borrelia burgdorferi in response to mammalian host signals provides insight into RpoS function during the enzootic cycle. Mol Microbiol 65:1193-1217 (Pubitemid 47262822)
23. Charon NW, Goldstein SF, Marko M et al (2009) The flat-ribbon configuration of the periplasmic flagella of Borrelia burgdorferi and its relationship to motility and morphology. J Bacteriol 191:600-607
24. Chu HJ, Chavez LG Jr, Blumer BM et al (1992) Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin. J Am Vet Med Assoc 201:403-411
25. Comstock LE, Thomas DD (1989) Penetration of endothelial cell monolayers by Borrelia burgdorferi. Infect Immun 57:1626-1628 (Pubitemid 19114190)
26. Connolly SE, Benach JL (2005) The versatile roles of antibodies in Borrelia infections. Nat Rev Microbiol 3:411-420 (Pubitemid 40590383)
27. Coutte L, Botkin DJ, Gao L et al (2009) Detailed analysis of sequence changes occurring during vlsE antigenic variation in the mouse model of Borrelia burgdorferi infection. PLoS Pathog 5:e1000293
28. Crother TR, Champion CI, Whitelegge JP et al (2004) Temporal analysis of the antigenic composition of Borrelia burgdorferi during infection in rabbit skin. Infect Immun 72:5063-5072 (Pubitemid 39223390)
29. Dai J, Wang P, Adusumilli S et al (2009) Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. Cell Host Microbe 6:482-492
30. Daix V, Schroeder H, Praet N et al (2007) Ixodes ticks belonging to the Ixodes ricinus complex encode a family of anticomplement proteins. Insect Mol Biol 16:155-166 (Pubitemid 46376338)
31. Dandache P, Nadelman RB (2008) Erythema migrans. Infect Dis Clin N Am 22:235-260 vi
32. Das S, Banerjee G, DePonte K et al (2001) Salp25D, an Ixodes scapularis antioxidant, is 1 of 14 immunodominant antigens in engorged tick salivary glands. J Infect Dis 184:1056-1064
33. Dennis VA, Dixit S, O'Brien SM et al (2009) Live Borrelia burgdorferi spirochetes elicit inflammatory mediators from human monocytes via the Toll-like receptor signaling pathway. Infect Immun 77:1238-1245
34. Ding W, Huang X, Yang X et al (2000) Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. J Mol Biol 302:1153-1164
35. Dressler F, Whalen JA, Reinhardt BN et al (1993) Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 167:392-400
36. Drouin EE, Glickstein L, Kwok WW et al (2008) Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol Immunol 45:2323-2332
37. Dykhuizen DE, Baranton G (2001) The implications of a low rate of horizontal transfer in Borrelia. Trends Microbiol 9:344-350 (Pubitemid 32575279)
38. Earnhart CG, Marconi RT (2007a) Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens. Vaccine 25:3419-3427 (Pubitemid 46527987)
39. Earnhart CG, Marconi RT (2007b) An octavalent Lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences. Hum Vaccin 3:281-289
40. Earnhart CG, Marconi RT (2007c) OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine. Clin Vaccine Immunol 14:628-634
41. Earnhart CG, Buckles EL, Dumler JS et al (2005) Demonstration of OspC type diversity in invasive human lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response. Infect Immun 73:7869-7877 (Pubitemid 41740270)
42. Ekerfelt C, Forsberg P, Svenvik M et al (1999) Asymptomatic Borrelia-seropositive individuals display the same incidence of Borrelia-specific interferon-gamma (IFN-gamma)-secreting cells in blood as patients with clinical Borrelia infection. Clin Exp Immunol 115:498-502 (Pubitemid 29130366)
43. Embers ME, Alvarez X, Ooms T et al (2008) The failure of immune response evasion by linear plasmid 28-1-deficient Borrelia burgdorferi is attributable to persistent expression of an outer surface protein. Infect Immun 76:3984-3991
44. Exner MM, Wu X, Blanco DR et al (2000) Protection elicited by native outer membrane protein Oms66 (p66) against host-adapted Borrelia burgdorferi: conformational nature of bactericidal epitopes. Infect Immun 68:2647-2654 (Pubitemid 30253838)
45. Fikrig E, Barthold SW, Kantor FS et al (1990) Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250:553-556 (Pubitemid 120031784)
46. Fikrig E, Barthold SW, Kantor FS et al (1991) Protection of mice from Lyme borreliosis by oral vaccination with Escherichia coli expressing OspA. J Infect Dis 164:1224-1227
47. Fikrig E, Barthold SW, Marcantonio N et al (1992a) Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect Immun 60:657-661
48. Fikrig E, Telford SR 3rd, Barthold SW et al (1992b) Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci USA 89:5418-5421
49. Fikrig E, Barthold SW, Sun W et al (1997) Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity. Immunity 6:531-539 (Pubitemid 27239344)
50. Fikrig E, Chen M, Barthold SW et al (1999) Borrelia burgdorferi erpT expression in the arthropod vector and murine host. Mol Microbiol 31:281-290 (Pubitemid 29012167)
51. Fiserova L, Cerna K, Horka H et al (2008) Two ways of experimental infection of Ixodes ricinus ticks (Acari: Ixodidae) with spirochetes of Borrelia burgdorferi sensu lato complex. Folia Parasitol 55:150-154 (Pubitemid 351988555)
52. Francischetti IM, Valenzuela JG, Andersen JF et al (2002) Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 99:3602-3612 (Pubitemid 34534529)
53. Garon CF, Dorward DW, Corwin MD (1989) Structural features of Borrelia burgdorferi - the Lyme disease spirochete: silver staining for nucleic acids. Scanning Microsc Suppl 3:109-115 (Pubitemid 20060233)
54. Gilmore RD Jr, Mbow ML (1999) Conformational nature of the Borrelia burgdorferi B31 outer surface protein C protective epitope. Infect Immun 67:5463-5469
55. Gilmore RD Jr, Kappel KJ, Dolan MC et al (1996) Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect Immun 64:2234-2239 (Pubitemid 26167235)
56. Gilmore RD Jr, Murphree RL, James AM et al (1999) The Borrelia burgdorferi 37-kilodalton immunoblot band (P37) used in serodiagnosis of early Lyme disease is the flaA gene product. J Clin Microbiol 37:548-552 (Pubitemid 29091262)
57. Girschick HJ, Huppertz HI, Russmann H et al (1996) Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol Int 16:125-132 (Pubitemid 26317052)
58. Grab DJ, Lanners H, Martin LN et al (1999) Interaction of Borrelia burgdorferi with peripheral blood fibrocytes, antigen-presenting cells with the potential for connective tissue targeting. Mol Med 5:46-54 (Pubitemid 29282096)
59. Gross DM, Forsthuber T, Tary-Lehmann M et al (1998) Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281:703-706 (Pubitemid 28390407)
60. Gruntar I, Malovrh T, Murgia R et al (2001) Conversion of Borrelia garinii cystic forms to motile spirochetes in vivo. APMIS 109:383-388 (Pubitemid 32640886)
61. Guo BP, Brown EL, Dorward DW et al (1998) Decorin-binding adhesins from Borrelia burgdorferi. Mol Microbiol 30:711-723 (Pubitemid 28528591)
62. Hagman KE, Lahdenne P, Popova TG et al (1998) Decorin-binding protein of Borrelia burgdorferi is encoded within a two-gene operon and is protective in the murine model of Lyme borreliosis. Infect Immun 66:2674-2683 (Pubitemid 28261769)
63. Hagman KE, Yang X, Wikel SK et al (2000) Decorin-binding protein A (DbpA) of Borrelia burgdorferi is not protective when immunized mice are challenged via tick infestation and correlates with the lack of DbpA expression by B. burgdorferi in ticks. Infect Immun 68:4759-4764 (Pubitemid 30497751)
64. Hanson MS, Cassatt DR, Guo BP et al (1998) Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun 66:2143-2153 (Pubitemid 28194114)
65. Hanson MS, Patel NK, Cassatt DR et al (2000) Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis. Infect Immun 68:6457-6460
66. Hitt E (2002) Poor sales trigger vaccine withdrawal. Nat Med 8:311-312
67. Hojgaard A, Eisen RJ, Piesman J (2008) Transmission dynamics of Borrelia burgdorferi s.s. during the key third day of feeding by nymphal Ixodes scapularis (Acari: Ixodidae). J Med Entomol 45:732-736
68. Hovius JW, de Jong MA, den Dunnen J et al (2008) Salp15 binding to DC-SIGN inhibits cytokine expression by impairing both nucleosome remodeling and mRNA stabilization. PLoS Pathog 4:e31
69. Humair P, Gern L (2000) The wild hidden face of Lyme borreliosis in Europe. Microbes Infect 2:915-922 (Pubitemid 30483187)
70. Ikushima M, Matsui K, Yamada F et al (2000) Specific immune response to a synthetic peptide derived from outer surface protein C of Borrelia burgdorferi predicts protective borreliacidal antibodies. FEMS Immunol Med Microbiol 29:15-21
71. Jarefors S, Janefjord CK, Forsberg P et al (2007) Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals. Clin Exp Immunol 147:18-27 (Pubitemid 44915551)
72. Jobe DA, Lovrich SD, Schell RF et al (2003) C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease. Clin Diagn Lab Immunol 10:573-578 (Pubitemid 36890440)
73. Johnson RC, Hyde FW, Rumpel CM (1984) Taxonomy of the Lyme disease spirochetes. Yale J Biol Med 57:529-537 (Pubitemid 15151041)
74. Johnson RC, Kodner C, Russell M (1986a) Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect Immun 54:897-898 (Pubitemid 17186469)
75. Johnson RC, Kodner CL, Russell ME (1986b) Vaccination of hamsters against experimental infection with Borrelia burgdorferi. Zentralbl Bakteriol Mikrobiol Hyg A 263:45-48 (Pubitemid 17030836)
76. Jovicic V, Grego EM, Lako BL et al (2003) Improved serodiagnosis of early Lyme borreliosis: immunoblot with local Borrelia afzelii strain. APMIS 111:1053-1059 (Pubitemid 37521898)
77. Juncadella IJ, Garg R, Ananthnarayanan SK et al (2007) T-cell signaling pathways inhibited by the tick saliva immunosuppressor, Salp15. FEMS Immunol Med Microbiol 49:433-438 (Pubitemid 46435023)
78. Kalish RA, Leong JM, Steere AC (1993) Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 61:2774-2779 (Pubitemid 23182268)
79. Klempner MS, Noring R, Rogers RA (1993) Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. J Infect Dis 167:1074-1081 (Pubitemid 23115595)
80. Kochi SK, Johnson RC (1988) Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect Immun 56:314-321 (Pubitemid 18040491)
81. Kochi SK, Johnson RC, Dalmasso AP (1991) Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex. J Immunol 146:3964-3970
82. Koide S, Yang X, Huang X et al (2005) Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J Mol Biol 350:290-299 (Pubitemid 40805463)
83. Korshus JB, Munderloh UG, Bey RF et al (2004) Experimental infection of dogs with Borrelia burgdorferi sensu stricto using Ixodes scapularis ticks artificially infected by capillary feeding. Med Microbiol Immunol 193:27-34 (Pubitemid 40585303)
84. Kotsyfakis M, Sa-Nunes A, Francischetti IM et al (2006) Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis. J Biol Chem 281:26298-26307 (Pubitemid 44401838)
85. Kotsyfakis M, Karim S, Andersen JF et al (2007) Selective cysteine protease inhibition contributes to blood-feeding success of the tick Ixodes scapularis. J Biol Chem 282:29256-29263 (Pubitemid 350043343)
86. Kotsyfakis M, Anderson JM, Andersen JF et al (2008) Cutting edge: Immunity against a "silent" salivary antigen of the Lyme vector Ixodes scapularis impairs its ability to feed. J Immunol 181:5209-5212
87. Kraiczy P, Skerka C, Brade V et al (2001a) Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi. Infect Immun 69:7800-7809 (Pubitemid 33086611)
88. Kraiczy P, Skerka C, Kirschfink M et al (2001b) Immune evasion of Borrelia burgdorferi by acquisition of human complement regulators FHL-1/reconectin and Factor H. Eur J Immunol 31:1674-1684 (Pubitemid 32547329)
89. Krupka M, Belakova J, Sebestova M et al (2005) Isolation and purification of recombinant outer surface protein C (rOspC) of Borrelia burgdorferi sensu lato. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:261-264
90. Krupka M, Raska M, Belakova J et al (2007) Biological aspects of Lyme disease spirochetes: unique bacteria of the Borrelia burgdorferi species group. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151:175-186
91. Krupka M, Raska M, Horynova M et al. (2008) Preparation of recombinant non-lipidated apyrogenic Borrelia burgdorferi Outer surface protein C. Alergie 10(suppl 2):88 (in Czech)
92. Kurtenbach K, Dizij A, Voet P et al (1997) Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies. Vaccine 15:1670-1674 (Pubitemid 27445746)
93. Kurtenbach K, Hanincova K, Tsao JI et al (2006) Fundamental processes in the evolutionary ecology of Lyme borreliosis. Nat Rev Microbiol 4:660-669
94. Kurtti TJ, Munderloh UG, Krueger DE et al (1993) Adhesion to and invasion of cultured tick (Acarina: Ixodidae) cells by Borrelia burgdorferi (Spirochaetales: Spirochaetaceae) and maintenance of infectivity. J Med Entomol 30:586-596
95. Kyckova K, Kopecky J (2006) Effect of tick saliva on mechanisms of innate immune response against Borrelia afzelii. J Med Entomol 43:1208-1214 (Pubitemid 44862955)
96. Labandeira-Rey M, Baker EA, Skare JT (2001) VraA (BBI16) protein of Borrelia burgdorferi is a surface-exposed antigen with a repetitive motif that confers partial protection against experimental Lyme borreliosis. Infect Immun 69:1409-1419
97. LaFleur RL, Dant JC, Wasmoen TL et al (2009) Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine Immunol 16:253-259
98. Lawrenz MB, Wooten RM, Norris SJ (2004) Effects of vlsE complementation on the infectivity of Borrelia burgdorferi lacking the linear plasmid lp28-1. Infect Immun 72:6577-6585 (Pubitemid 39425439)
99. Leboulle G, Crippa M, Decrem Y et al (2002) Characterization of a novel salivary immunosuppressive protein from Ixodes ricinus ticks. J Biol Chem 277:10083-10089 (Pubitemid 34968118)
100. Levy SA (2002) Use of a C6 ELISA test to evaluate the efficacy of a whole-cell bacterin for the prevention of naturally transmitted canine Borrelia burgdorferi infection. Vet Ther 3:420-424
101. Liang FT, Jacobs MB, Bowers LC et al (2002) An immune evasion mechanism for spirochetal persistence in Lyme borreliosis. J Exp Med 195:415-422 (Pubitemid 34461295)
102. Liang FT, Yan J, Mbow ML et al (2004) Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses. Infect Immun 72:5759-5767 (Pubitemid 39303686)
103. Livengood JA, Gilmore RD Jr (2006) Invasion of human neuronal and glial cells by an infectious strain of Borrelia burgdorferi. Microbes Infect 8:2832-2840 (Pubitemid 44914125)
104. Lovrich SD, Jobe DA, Schell RF et al (2005) Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters. Clin Diagn Lab Immunol 12:746-751 (Pubitemid 41175304)
105. Lovrich SD, La Fleur RL, Jobe DA et al (2007) Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease. Clin Vaccine Immunol 14:635-637
106. Luke CJ, Carner K, Liang X et al (1997) An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J Infect Dis 175:91-97 (Pubitemid 27020829)
107. Lunemann JD, Zarmas S, Priem S et al (2001) Rapid typing of Borrelia burgdorferi sensu lato species in specimens from patients with different manifestations of Lyme borreliosis. J Clin Microbiol 39:1130-1133 (Pubitemid 32209734)
108. Ma Y, Sturrock A, Weis JJ (1991) Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect Immun 59:671-678
109. MacDonald AB (2006a) Plaques of Alzheimer's disease originate from cysts of Borrelia burgdorferi, the Lyme disease spirochete. Med Hypotheses 67:592-600
110. MacDonald AB (2006b) Spirochetal cyst forms in neurodegenerative disorders, hiding in plain sight. Med Hypotheses 67:819-832
111. Malawista SE, de Boisfleury Chevance A (2008) Clocking the Lyme spirochete. PLoS One 3:e1633
112. Marconi RT, Earnhart CG (2010) Lyme disease vaccines. In: Samuels DS, Radolf JD (eds) Borrelia, molecular biology, host interaction and pathogenesis. Caister Academic Press, Norfolk
113. Miklossy J, Kasas S, Zurn AD et al (2008) Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation 5:40
114. Montgomery RR, Nathanson MH, Malawista SE (1993) The fate of Borrelia burgdorferi, the agent for Lyme disease, in mouse macrophages. Destruction, survival, recovery. J Immunol 150:909-915 (Pubitemid 23133670)
115. Montgomery RR, Lusitani D, De Boisfleury Chevance A et al (2004) Tick saliva reduces adherence and area of human neutrophils. Infect Immun 72:2989-2994 (Pubitemid 38542429)
116. Mullegger RR, McHugh G, Ruthazer R et al (2000) Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. J Invest Dermatol 115:1115-1123 (Pubitemid 32037459)
117. Murgia R, Cinco M (2004) Induction of cystic forms by different stress conditions in Borrelia burgdorferi. APMIS 112:57-62 (Pubitemid 38297168)
118. Murgia R, Piazzetta C, Cinco M (2002) Cystic forms of Borrelia burgdorferi sensu lato: induction, development, and the role of RpoS. Wien Klin Wochenschr 114:574-579 (Pubitemid 34847346)
119. Narasimhan S, Koski RA, Beaulieu B et al (2002) A novel family of anticoagulants from the saliva of Ixodes scapularis. Insect Mol Biol 11:641-650 (Pubitemid 35450729)
120. Nazario S, Das S, de Silva AM et al (1998) Prevention of Borrelia burgdorferi transmission in guinea pigs by tick immunity. Am J Trop Med Hyg 58:780-785 (Pubitemid 28307398)
121. Pachner AR, Basta J, Delaney E et al (1995) Localization of Borrelia burgdorferi in murine Lyme borreliosis by electron microscopy. Am J Trop Med Hyg 52:128-133
122. Pal U, Li X, Wang T et al (2004) TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi. Cell 119:457-468 (Pubitemid 39482346)
123. Panelius J, Meri T, Seppala I et al (2008) Outer surface protein E antibody response and its effect on complement factor H binding to OspE in Lyme borreliosis. Microbes Infect 10:135-142
124. Pechova J, Stepanova G, Kovar L et al (2002) Tick salivary gland extract-activated transmission of Borrelia afzelii spirochaetes. Folia Parasitol 49:153-159 (Pubitemid 34780670)
125. Persing DH, Rutledge BJ, Rys PN et al (1994) Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients. J Infect Dis 169:668-672 (Pubitemid 24063020)
126. Petzke MM, Brooks A, Krupna MA et al (2009) Recognition of Borrelia burgdorferi, the Lyme disease spirochete, by TLR7 and TLR9 induces a type I IFN response by human immune cells. J Immunol 183:5279-5292
127. Piesman J, Dolan MC (2002) Protection against Lyme disease spirochete transmission provided by prompt removal of nymphal Ixodes scapularis (Acari: Ixodidae). J Med Entomol 39:509-512 (Pubitemid 135700286)
128. Policastro PF, Schwan TG (2003) Experimental infection of Ixodes scapularis larvae (Acari: Ixodidae) by immersion in low passage cultures of Borrelia burgdorferi. J Med Entomol 40:364-370 (Pubitemid 37399432)
129. Pozsgay V, Kubler-Kielb J (2007) Synthesis of an experimental glycolipoprotein vaccine against Lyme disease. Carbohydr Res 342:621-626 (Pubitemid 46161417)
130. Preac-Mursic V, Wilske B, Patsouris E et al (1992) Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection 20:342-349 (Pubitemid 23009995)
131. Prevot PP, Adam B, Boudjeltia KZ et al (2006) Anti-hemostatic effects of a serpin from the saliva of the tick Ixodes ricinus. J Biol Chem 281:26361-26369 (Pubitemid 44401844)
132. Probert WS, Crawford M, Cadiz RB et al (1997) Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J Infect Dis 175:400-405 (Pubitemid 27052246)
133. Ramamoorthi N, Narasimhan S, Pal U et al (2005) The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature 436:573-577 (Pubitemid 41112932)
134. Rittig MG, Krause A, Haupl T et al (1992) Coiling phagocytosis is the preferential phagocytic mechanism for Borrelia burgdorferi. Infect Immun 60:4205-4212
135. Rojko T, Ruzic-Sabljic E, Strle F et al (2005) Prevalence and incidence of Lyme borreliosis among Slovene forestry workers during the period of tick activity. Wien Klin Wochenschr 117:219-225 (Pubitemid 40645915)
136. Sanogo YO, Reipert S, Halouzka J et al (2000) Isolation and morphological characterization of mosquito spirochetes from a Lyme disease endemic area. Ann N Y Acad Sci 916:672-675 (Pubitemid 32061160)
137. Sa-Nunes A, Bafica A, Lucas DA et al (2007) Prostaglandin E2 is a major inhibitor of dendritic cell maturation and function in Ixodes scapularis saliva. J Immunol 179:1497-1505
138. Schaible UE, Kramer MD, Eichmann K et al (1990) Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci USA 87:3768-3772
139. Schaible UE, Wallich R, Kramer MD et al (1993) Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype. Vaccine 11:1049-1054 (Pubitemid 23304003)
140. Scheiblhofer S, Weiss R, Durnberger H et al (2003) A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes Infect 5:939-946 (Pubitemid 36986569)
141. Schulte-Spechtel U, Fingerle V, Goettner G et al (2006) Molecular analysis of decorin-binding protein A (DbpA) reveals five major groups among European Borrelia burgdorferi sensu lato strains with impact for the development of serological assays and indicates lateral gene transfer of the dbpA gene. Int J Med Microbiol 296(suppl 40):250-266 (Pubitemid 43668611)
142. Seemanapalli SV, Xu Q, McShan K et al (2010) Outer surface protein C is a dissemination-facilitating factor of Borrelia burgdorferi during mammalian infection. PLoS ONE 5:e15830
143. Shin JJ, Glickstein LJ, Steere AC (2007) High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis. Arthritis Rheum 56:1325-1335 (Pubitemid 46608658)
144. Shin OS, Isberg RR, Akira S et al (2008) Distinct roles for MyD88 and Toll-like receptors 2, 5, and 9 in phagocytosis of Borrelia burgdorferi and cytokine induction. Infect Immun 76:2341-2351
145. Sigal LH, Zahradnik JM, Lavin P et al (1998) A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 339:216-222 (Pubitemid 28350163)
146. SikandVK, Halsey N, Krause PJ et al (2001) Safety andimmunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial. Pediatrics 108:123-128 (Pubitemid 32592015)
147. Sjowall J, Carlsson A, Vaarala O et al (2005) Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor-alpha and interleukin-12 in asymptomatic individuals in response to live spirochetes. Clin Exp Immunol 141:89-98 (Pubitemid 40904645)
148. Skallova A, Iezzi G, Ampenberger F et al (2008) Tick saliva inhibits dendritic cell migration, maturation, and function while promoting development of Th2 responses. J Immunol 180:6186-6192
149. Srivastava SY, de Silva AM (2008) Reciprocal expression of ospA and ospC in single cells of Borrelia burgdorferi. J Bacteriol 190:3429-3433
150. Srivastava SY, de Silva AM (2009) Characterization of Borrelia burgdorferi aggregates. Vector Borne Zoonotic Dis 9:323-329
151. Steere AC, Schoen RT, Taylor E (1987) The clinical evolution of Lyme arthritis. Ann Intern Med 107:725-731 (Pubitemid 18041872)
152. Steere AC, Sikand VK, Meurice F et al (1998) Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 339:209-215 (Pubitemid 28350162)
153. Steere AC, Gross D, Meyer AL et al (2001) Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis. J Autoimmun 16:263-268 (Pubitemid 32567513)
154. Steere AC, Sikand VK, Schoen RT et al (2003) Asymptomatic infection with Borrelia burgdorferi. Clin Infect Dis 37:528-532 (Pubitemid 37011776)
155. Steere AC, McHugh G, Damle N et al (2008) Prospective study of serologic tests for Lyme disease. Clin Infect Dis 47:188-195 (Pubitemid 351920619)
156. Stover CK, Bansal GP, Hanson MS et al (1993) Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med 178:197-209 (Pubitemid 23173255)
157. Stricker RB (2007) Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin Infect Dis 45:149-157
158. Stricker RB, Johnson L (2008) Re: prolonged Lyme disease treatment: enough is enough. Neurology 71:1380 (author reply 1380-1381)
159. Stubs G, Fingerle V, Wilske B et al (2009) Acylated cholesteryl galactosides are specific antigens of borrelia causing Lyme disease and frequently induce antibodies in late stages of disease. J Biol Chem 284:13326-13334
160. Stubs G, Rupp B, Schumann RR et al (2010) Chemoenzymatic synthesis of a glycolipid library and elucidation of the antigenic epitope for construction of a vaccine against Lyme disease. Chemistry 16:3536-3544
161. Thomas DD, Cadavid D, Barbour AG (1994) Differential association of Borrelia species with cultured neural cells. J Infect Dis 169:445-448 (Pubitemid 24045612)
162. Tilly K, Bestor A, Jewett MW et al (2007) Rapid clearance of Lyme disease spirochetes lacking OspC from skin. Infect Immun 75:1517-1519 (Pubitemid 46385847)
163. Tilly K, Bestor A, Dulebohn DP et al (2009) OspC-independent infection and dissemination by host-adapted Borrelia burgdorferi. Infect Immun 77:2672-2682
164. Topfer KH, Straubinger RK (2007) Characterization of the humoral immune response in dogs after vaccination against Lyme borreliosis agent: a study with five commercial vaccines using two different vaccination schedules. Vaccine 25:314-326 (Pubitemid 44856078)
165. Tuhackova J, Belakova J, Krupka M et al (2005) Testing of the Biocan B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:297-302
166. Tuominen-Gustafsson H, Penttinen M, Hytönen J et al (2006) Use of CFSE staining of borreliae in studies on the interaction between borreliae and human neutrophils. BMC Microbiol 6:92
167. Tyson KR, Elkins C, de Silva AM (2008) A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin. J Immunol 180:3964-3968
168. Ulbrandt ND, Cassatt DR, Patel NK et al (2001) Conformational nature of the Borrelia burgdorferi decorin binding proteinA epitopes that elicit protective antibodies. Infect Immun 69:4799-4807 (Pubitemid 32674458)
169. Valenzuela JG, Charlab R, Mather TN et al (2000) Purification, cloning, and expression of a novel salivary anticomplement protein from the tick, Ixodes scapularis. J Biol Chem 275:18717-18723 (Pubitemid 30422830)
170. Wallich R, Schaible UE, Simon MM et al (1989) Cloning and sequencing of the gene encoding the outer surface protein A (OspA) of a European Borrelia burgdorferi isolate. Nucleic Acids Res 17:8864
171. Wallich R, Siebers A, Jahraus O et al (2001) DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease. Infect Immun 69:2130-2136 (Pubitemid 32239678)
172. Wallich R, Pattathu J, Kitiratschky V et al (2005) Identification and functional characterization of complement regulator-acquiring surface protein 1 of the Lyme disease spirochetes Borrelia afzelii and Borrelia garinii. Infect Immun 73:2351-2359 (Pubitemid 40470838)
173. Wang IN, Dykhuizen DE, Qiu W et al (1999) Genetic diversity of OspC in a local population of Borrelia burgdorferi sensu stricto. Genetics 151:15-30 (Pubitemid 29031873)
174. Widhe M, Jarefors S, Ekerfelt C et al (2004) Borrelia-specific interferon-gamma and interleukin-4 secretion in cerebrospinal fluid and blood during Lyme borreliosis in humans: association with clinical outcome. J Infect Dis 189:1881-1891 (Pubitemid 38657224)
175. Wiedemann C, Milward F (1999) Efficacy and safety studies with a new vaccine against Lyme borreliosis in dogs (Merilyme (R)). Tierarztl Umsch 54:242-249
176. Wikle RE, Fretwell B, Jarecki M et al (2006) Canine Lyme disease: one-year duration of immunity elicited with a canine OspA monovalent Lyme disease vaccine. Int J Appl Res Vet Med 4:23-28
177. Willett TA, Meyer AL, Brown EL et al (2004) An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc Natl Acad Sci USA 101:1303-1308 (Pubitemid 38182684)
178. Wilske B, Preac-Mursic V, Jauris S et al (1993) Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi. Infect Immun 61:2182-2191 (Pubitemid 23145929)
179. Wormser GP, McKenna D, Carlin J et al (2005) Brief communication: hematogenous dissemination in early Lyme disease. Ann Intern Med 142:751-755 (Pubitemid 40593777)
180. Wormser GP, Dattwyler RJ, Shapiro ED et al (2006) The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43:1089-1134 (Pubitemid 44637131)
181. Xu Q, Seemanapalli SV, McShan K et al (2006) Constitutive expression of outer surface protein C diminishes the ability of Borrelia burgdorferi to evade specific humoral immunity. Infect Immun 74:5177-5184 (Pubitemid 44300436)
182. Xu Q, McShan K, Liang FT (2007a) Identification of an ospC operator critical for immune evasion of Borrelia burgdorferi. Mol Microbiol 64:220-231 (Pubitemid 46435034)
183. Xu Q, Seemanapalli SV, Reif KE et al (2007b) Increasing the recruitment of neutrophils to the site of infection dramatically attenuates Borrelia burgdorferi infectivity. J Immunol 178:5109-5115 (Pubitemid 46595294)
184. Xu Q, McShan K, Liang FT (2008a) Essential protective role attributed to the surface lipoproteins of Borrelia burgdorferi against innate defences. Mol Microbiol 69:15-29 (Pubitemid 351832757)
185. Xu Q, McShan K, Liang FT (2008b) Verification and dissection of the ospC operator by using flaB promoter as a reporter in Borrelia burgdorferi. Microb Pathog 45:70-78
186. Zakovska A, Capkova L, Sery O et al (2006) Isolation of Borrelia afzelii from overwintering Culex pipiens biotype molestus mosquitoes. Ann Agric Environ Med 13:345-348 (Pubitemid 46064506)
187. Zambrano MC, Beklemisheva AA, Bryksin AV et al (2004) Borrelia burgdorferi binds to, invades, and colonizes native type I collagen lattices. Infect Immun 72:3138-3146 (Pubitemid 38697734)
188. Zhang JR, Norris SJ (1998) Genetic variation of the Borrelia burgdorferi gene vlsE involves cassette-specific, segmental gene conversion. Infect Immun 66:3698-3704
189. Zhioua E, Rodhain F, Binet P et al (1997) Prevalence of antibodies to Borrelia burgdorferi in forestry workers of Ile de France, France. Eur J Epidemiol 13:959-962 (Pubitemid 28046728)